Avenue TherapeuticsATXI -8.35%33 Current Ratio is 1.94 as of Mar. 2026, which is 27% below its 10-year median of 2.65. GuruFocus rates ATXI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Avenue Therapeutics ranks worse than 69.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Avenue Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 1.94.
Avenue Therapeutics has a current ratio of 1.94. It generally indicates good short-term financial strength.
The historical rank and industry rank for Avenue Therapeutics's Current Ratio or its related term are showing as below:
ATXI'
s Current Ratio Range Over the Past 10 Years
Min: 0.03 Med: 2.65 Max: 13.15
Current: 1.94
During the past 11 years, Avenue Therapeutics's highest Current Ratio was 13.15. The lowest was 0.03. And the median was 2.65.
ATXI's Current Ratio is ranked worse than 69.64% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs ATXI: 1.94
Avenue Therapeutics (OTCPK:ATXI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Avenue Therapeutics Current Ratio Related Terms
Avenue Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Avenue Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATXI vs PTIX, EVFM, AGTX: Current Ratio Comparison
For the Biotechnology subindustry, Avenue Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (ATXI) has a Current Ratio of 1.94 as of Mar. 2026. This is 27% below median its historical median of 2.65. Over the past decade, Avenue Therapeutics' Current Ratio has ranged from 0.03 to 13.15. According to the industry distribution chart, Avenue Therapeutics ranks #984 out of 1413 companies in the Biotechnology industry, placing it in the top 69.6%.
Is Avenue Therapeutics' Current Ratio too high?
Avenue Therapeutics' current Current Ratio of 1.94 is 27% below median its 10-year median of 2.65. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 13.15. The Biotechnology industry median Current Ratio is 3.89. Avenue Therapeutics' value of 1.94 is 50.1% below this industry median. Based on the distribution chart, Avenue Therapeutics ranks #984 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Avenue Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' Current Ratio compare to PTIX and EVFM?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #984 out of 1413 companies for Current Ratio. This places Avenue Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Avenue Therapeutics' value of 1.94 is 50.1% below this benchmark. Historically, Avenue Therapeutics' own Current Ratio has ranged from 0.03 to 13.15 over the past decade. While the company's 10-year median is 2.65 vs. the industry median of 3.89, Avenue Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current Current Ratio of 1.94 is 50.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current Current Ratio is 1.94, which is 27% below median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current Current Ratio of 1.94. The current Current Ratio is 1.94, which is 27% below median its 10-year median of 2.65 and 50.1% below the Biotechnology industry median of 3.89. Avenue Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current Current Ratio is 1.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
33GF Score
Get the complete analysis for ATXI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
